Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib to Restore Radioiodine Sensitivity in Thyroid Cancer
NCT03469011Phase 1Terminated
- Sponsor
- American Health Staffing Group
- Start
- Sep 2018
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imatinib in papillary thyroid cancer (PTC), sponsored by American Health Staffing Group. Primary endpoint: Restore iodine uptake at 3 months. Started Sep 2018; status: terminated.
02
Drugs
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on NCT03469011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03469011.